SUTRO BIOPHARMA, INC. 8-K

What Happened Sutro Biopharma, Inc. (STRO) filed a Form 8-K on May 14, 2026 (Item 2.02) to announce its financial results for the quarter ended March 31, 2026. The company issued a press release with the quarterly results, which is attached to the filing as Exhibit 99.1. The 8-K was signed by CFO Gregory Chow on May 14, 2026.

Key Details

• Filing date: May 14, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Period covered: Quarter ended March 31, 2026.
• Disclosure: Press release announcing quarterly financial results attached as Exhibit 99.1 to the 8-K.
• Signature: Report signed by Gregory Chow, Chief Financial Officer, on May 14, 2026.

Why It Matters This 8-K is the company’s official disclosure that quarterly earnings and related financial information have been released. Investors should review the attached press release (Exhibit 99.1) for revenue, earnings, guidance, or other material metrics that can affect the stock price and investment decisions. Because the 8-K itself does not list the figures, consult the press release and subsequent filings for specific numbers, trends, and management commentary on performance.